Experienced in Mycobacterium Avium Complex Infections

Thomas J. Vogl

Union Hospital, 
Wuhan, CN 
Experienced in Mycobacterium Avium Complex Infections
Union Hospital, 
Wuhan, CN 
OverviewLocationsClinical Research

Overview

Thomas Vogl practices in Wuhan, China. Vogl is rated as an Experienced expert by MediFind in the treatment of Mycobacterium Avium Complex Infections. Their top areas of expertise are Liver Cancer, Lung Metastases, Tonsillitis, Liver Embolization, and Prostatic Artery Embolization.

Their clinical research consists of co-authoring 931 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Mycobacterium Avium Complex Infections.

Locations

Union Hospital, Wuhan, 430022, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

The CArdiac Imaging RegistrY Study: Computed ToMogrAphy for Risk Stratification and Diagnostic Safety
The CArdiac Imaging RegistrY Study: Computed ToMogrAphy for Risk Stratification and Diagnostic Safety
Enrollment Status: Completed
Publish Date: April 03, 2025
A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm
A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Drug
Study Phase: Phase 3
An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: October 17, 2022
Intervention Type: Device, Drug
Study Phase: Phase 2
To Evaluate the Safety & Palliative Treatment Effect on Patients With Solid Cancers by Immunostimulating Interstitial Laser Thermotherapy (imILT)
To Evaluate the Safety & Palliative Treatment Effect on Patients With Solid Cancers by Immunostimulating Interstitial Laser Thermotherapy (imILT)
Enrollment Status: Terminated
Publish Date: January 30, 2019
Intervention Type: Device
Study Phase: Not Applicable
The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)
The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)
Enrollment Status: Completed
Publish Date: May 07, 2018
Intervention Type: Device, Procedure
Study Phase: Not Applicable
A Prospective, Multicenter Clinical Study to Evaluate the Clinical Outcomes of Targeted Radiofrequency Ablation and Vertebral Augmentation to Treat Painful Metastatic Vertebral Body Tumor(s)
A Prospective, Multicenter Clinical Study to Evaluate the Clinical Outcomes of Targeted Radiofrequency Ablation and Vertebral Augmentation to Treat Painful Metastatic Vertebral Body Tumor(s)
Enrollment Status: Terminated
Publish Date: January 20, 2017
Intervention Type: Device
Study Phase: Not Applicable
View 5 Less Clinical Trials

931 Total Publications

Standardized Myocardial T1 and T2 Relaxation Times: Defining Age- and Comorbidity-Adjusted Reference Values for Improved CMR-Based Tissue Characterization.
Standardized Myocardial T1 and T2 Relaxation Times: Defining Age- and Comorbidity-Adjusted Reference Values for Improved CMR-Based Tissue Characterization.
Journal: Journal of clinical medicine
Published: August 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Vogl's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 134 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile